 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Enrollment change, Trial completion date, Trial termination: A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) (clinicaltrials.gov) - May 12, 2021
P2a, N=60, Terminated, Sponsor: Ionis Pharmaceuticals, Inc.
N=180 --> 60 | Trial completion date: Sep 2021 --> Apr 2021 | Recruiting --> Terminated; Business Decision to Terminate Study
- IONIS-ENAC-2.5Rx / Ionis
[VIRTUAL] Safety and Tolerability Demonstrated with Inhaled αENaC Antisense Oligonucleotide (ION-827359) in Patients with Cystic Fibrosis () - Mar 14, 2021 - Abstract #ATS2021ATS_3206;
N=180 --> 60 | Trial completion date: Sep 2021 --> Apr 2021 | Recruiting --> Terminated; Business Decision to Terminate Study These results demonstrate strong evidence of tolerability and safety at the doses and regimens tested and supports further investigation of ENaC ASO ION-827359 in patients with cystic fibrosis.
- ||| cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Trial completion, Trial completion date, Trial primary completion date: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Feb 4, 2021
P1/2, N=98, Completed, Sponsor: Ionis Pharmaceuticals, Inc.
These results demonstrate strong evidence of tolerability and safety at the doses and regimens tested and supports further investigation of ENaC ASO ION-827359 in patients with cystic fibrosis. Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020
- ||| cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Enrollment open: A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) (clinicaltrials.gov) - Nov 22, 2020
P2a, N=180, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Oct 2020 | Trial primary completion date: Jun 2020 --> Oct 2020 Not yet recruiting --> Recruiting
- IONIS-ENAC-2.5Rx / Ionis
[VIRTUAL] SAFETY, TOLERABILITY, AND TARGET ENGAGEMENT DEMONSTRATED WITH INHALED ENAC ANTISENSE OLIGONUCLEOTIDE (ION-827359) IN A PHASE 1 HEALTHY VOLUNTEER STUDY () - Oct 7, 2020 - Abstract #NACFC2020NACFC_818;
These results demonstrate strong evidence of tolerability and safety at the doses and regimens tested and supports further investigation of ENaC ASO ION-827359 in patients with cystic fibrosis. Furthermore, there was evidence of strong target engagement with this nebulized ASO.
- || cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Enrollment closed: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Jul 2, 2020
P1/2, N=98, Active, not recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Furthermore, there was evidence of strong target engagement with this nebulized ASO. Recruiting --> Active, not recruiting
- |||| cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
New P2a trial: A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) (clinicaltrials.gov) - Jun 22, 2020
P2a, N=180, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
- || cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Trial completion date, Trial primary completion date: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Nov 15, 2019
P1/2, N=88, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Oct 2019 --> Jun 2020
- ||| cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Phase classification, Enrollment change: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Mar 8, 2019
P1/2, N=88, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Trial completion date: Oct 2019 --> Jun 2020 | Trial primary completion date: Oct 2019 --> Jun 2020 Phase classification: P1 --> P1/2 | N=64 --> 88
- | cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
Enrollment open: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Nov 26, 2018
P1, N=56, Recruiting, Sponsor: Ionis Pharmaceuticals, Inc.
Phase classification: P1 --> P1/2 | N=64 --> 88 Not yet recruiting --> Recruiting
- | cofirasersen (IONIS-ENAC-2.5Rx) / Ionis
New P1 trial: A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis (clinicaltrials.gov) - Aug 26, 2018
P1, N=56, Not yet recruiting, Sponsor: Ionis Pharmaceuticals, Inc.